Skip to main content

Advertisement

SpringerLink
Log in

Immune checkpoint inhibitor using in cases with gestational trophoblastic diseases

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Gestational trophoblastic neoplasias (GTNs) are chemosensitive disorders with very high cure rates. However, individuals with chemoresistant diseases pass away as a result of their illness, necessitating the use of innovative medications. Immune checkpoint inhibitors (ICIs) are a critical component of the strategy for the management of drug-resistant GTD due to the high rate of PD-1 expression and the paternal genetic inheritance in GTNs. Immunotherapy is mentioned as a potential therapeutic approach for chemotherapy-resistant GTD in the most recent worldwide recommendations. However, multicenter worldwide collaborative studies are required to give additional evidence to detect and identify prognostic markers due to the rarity of GTDs and the dearth of data in the literature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Photograph 1
Fig. 1
Fig. 2
Photograph 2

Similar content being viewed by others

References

  1. Angiolo G, Silvestro C, Guerrieri ME, Damiano AG. Placental site trophoblastic tumor and epithelioid trophoblastic tumor: clinical and pathological features, prognostic variables and treatment strategy. Gynecol Oncol. 2019;153:684–93.

    Article  Google Scholar 

  2. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376:717–29.

    Article  PubMed  Google Scholar 

  3. Ning F, Hou H, Morse AN, Lash GE. Understanding and management of gestational trophoblastic disease. F1000Research. 2019;8:428.

    Article  CAS  Google Scholar 

  4. Kato M, Tanaka K, Takeuchi S. The nature of trophoblastic disease initiated by transplantation into immunosuppressed animals. Obstetric. 1982;142(5):497–505.

    Article  CAS  Google Scholar 

  5. Smith HO, Qualls CR, Prairie BA, Padilla LA, Rayburn WF, Key CR. Trends in gestational choriocarcinoma: a 27-year perspective. Obstet Gynecol. 2003;102(5):978–87.

    PubMed  Google Scholar 

  6. Shanmugaratnam K, Muir CS, Tow SH, Cheng WC, Christine B, Pedersen E. Rates per 100,000 births and incidence of choriocarcinoma and malignant mole in Singapore Chinese and Malays. Comparison with connecticut Norway and Sweden. Int J Cancer. 1971;8:165–75.

    Article  CAS  PubMed  Google Scholar 

  7. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol. 2003;4:670–8.

    Article  PubMed  Google Scholar 

  8. Elias KM, Berkowitz RS, Horowitz NS. State-of-the-art workup and initial management of newly diagnosed molar pregnancy and postmolar gestational trophoblastic neoplasia. J Natl Compr Cancer Netw. 2019;17:1396–401.

    Article  Google Scholar 

  9. Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Lurain JR, Massuger L. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1):86–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. -Abu-Rustum NR, Yashar CM, Bradley K et al (2003). Gestational Trophoblastic Neoplasia, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Online to NCCN.org.

  11. Mangili G, Lorusso D, Brown J, et al. Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. Int J Gynecol Cancer. 2014;24(Suppl. S3):S109–16.

    Article  PubMed  Google Scholar 

  12. Mangili G, Sabetta G, Cioffi R, Rabaiotti E, Candotti G, Pella F, Candiani M, Bergamini A. Current evidence on immunotherapy for gestational trophoblastic neoplasia (GTN). Cancers (Basel). 2022;3(14):2782.

    Article  Google Scholar 

  13. King JR, Wilson ML, Hetey S, Kiraly P, et al. Dysregulation of placental functions and immune pathways in complete hydatidiform moles. Int J Mol Sci. 2019;20:4999.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Frega G, Kepp O, Turchetti D, Rizzo A, Pantaleo MA, Brandi G. Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms. Transl Oncol. 2021;12: 101224.

    Article  Google Scholar 

  15. Szabolcsi Z, Demeter A, Kiraly P, et al. Epigenetic dysregulation of trophoblastic gene expression in gestational trophoblastic disease. Biomedicines. 2021;9:1935.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gomez S, Tabernacki T, Kobyra J, Roberts P, Chiappinelli KB. Combining epigenetic and immune therapy to overcome cancer resistance. Semin Cancer Biol. 2020;65:99–113.

    Article  CAS  PubMed  Google Scholar 

  17. Guleria I, Khosroshahi A, Ansari MJ, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med. 2005;202:231–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ghorani E, Kaur B, Fisher RA, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. The Lancet. 2017;390:2343–5.

    Article  Google Scholar 

  19. Fülöp V, Szigetvári I, Szepesi J, et al. 30 years’ experience in the treatment of low- risk gestational trophoblastic neoplasia in Hungary. J Reprod Med. 2010;55:253–7.

    PubMed  Google Scholar 

  20. Liu TL, Deppe G, Chang QT, Tan TT. Cerebral metastatic choriocarcinoma in the People’s Republic of China. Gynecol Oncol. 1983;15:166–70.

    Article  CAS  PubMed  Google Scholar 

  21. Lorch A, Neubauer A, Hackenthal M, et al. High-dose chemotherapy (HDCT) as second salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann Oncol. 2010;21:820e5.

    Article  Google Scholar 

  22. Salman L, Bouchard-Fortier G, Covens A. Immune checkpoint inhibitors for the treatment of gestational trophoblastic neoplasia: rationale, effectiveness, and future fertility. Curr Treat Options in Oncol. 2022;23:1035–43.

    Article  Google Scholar 

  23. Nakazaki H, Tokuyasu H, Takemoto Y, et al. Pulmonary metastatic choriocarcinoma from a burned-out testicular tumor. Intern Med. 2016;55:1481–5.

    Article  CAS  PubMed  Google Scholar 

  24. Ngan HY, Bende H, Benedet JL, Jones H, Montruccoli GC, Pecorelli S. FIGO Committee on gynecologic oncology. Gestational trophoblastic neoplasia FIGO 2000 staging and classification. Int J Gynaecol Obstet. 2003;83(Suppl S1):175–7.

    Article  PubMed  Google Scholar 

  25. Park HJ, Cho HY, Cha DH. The amniotic fluid cell-free transcriptome provides novel information about fetal development and placental cellular dynamics. Int J Mol Sci. 2021;22(5):2612.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Polterauer PVS, Poetsch N, Reinthaller A, Grimm C, Bartl T. Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: a case report. Gynecol Oncol Rep. 2021;37: 100817.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Lurain JR, Massuger L. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet. 2018;143(Suppl 2):79–85.

    Article  PubMed  Google Scholar 

  28. Tryakin A, Fedyanin M, Bulanov A, et al. Dose-reduced first cycle of chemotherapy for prevention of lifethreatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status. J Cancer Res Clin Oncol. 2018;144:1817–23.

    Article  CAS  PubMed  Google Scholar 

  29. Powles T, Savage PM, Stebbing J, et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer. 2007;12(96):732–7.

    Article  Google Scholar 

  30. Oechsle K, Honecker F, Cheng T, et al. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann Oncol. 2011;22:2654e60.

    Article  Google Scholar 

  31. Mego M, Svetlovska D, Miskovska V, et al. Phase II study of everolimus in refractory testicular germ cell tumors. Urol Oncol. 2016;34(3):122-e17.

    Article  Google Scholar 

  32. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 387(10027), 1540–1550.52-Huang M, Pinto A, Castillo RP, Slomovitz BM (2017). Complete serologic response to Pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma. J Clin Oncol. 2016;35:3172–4.

    Google Scholar 

  33. Abi Nahed R, Elkhoury Mikhael M, Reynaud D, et al. Role of NLRP7 in normal and malignant trophoblast cells. Biomedicines. 2022;10(2):252. https://doi.org/10.3390/biomedicines10020252.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Reynaud D, Abi Nahed R, Lemaitre N, et al. NLRP7 promotes choriocarcinoma growth and progression through the establishment of an immunosuppressive microenvironment. Cancers. 2021;13:2999.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Rustin GJ, Newlands ES, Begent RH, Dent J, Bagshawe KD. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 1989;7:900–3.

    Article  CAS  Google Scholar 

  36. Clair KH, Gallegos N, Bristow RE. Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: a case for immune checkpoint salvage therapy in trophoblastic tumors. Gynecol Oncol Rep ep. 2020;1(34): 100625.

    Article  Google Scholar 

  37. Athanassiou A, Begent RH, Newlands ES, Parker D, Rustin GJ, Bagshawe KD. Central nervous system metastases of choriocarcinoma. 23 years’ experience at charing cross hospital. Cancer. 1983;52:1728–35.

    Article  CAS  PubMed  Google Scholar 

  38. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98–106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;28(8):86.

    Article  Google Scholar 

  40. Zong L, Zhang M, WangW Wan X, Yang J, Xiang Y. PD-L1, B7–H3 and VISTA are highly expressed in gestational trophoblastic neoplasia. Histopathology. 2019;75(3):421–30.

    Article  PubMed  Google Scholar 

  41. Veras E, Kurman RJ, Wang T-L, Shih I-M. PD-L1 Expression in human placentas and gestational trophoblastic diseases. Int J Gynecol Pathol. 2017;36:146–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Bolze PA, Patrier S, Massardier J, et al. PD-L1 Expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes. Int J Gynecol Cancer. 2017;27:554–61.

    Article  PubMed  Google Scholar 

  43. Inaguma S, Wang Z, Lasota J, et al. Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1): analysis in 5536 cases revealed consistent expression in trophoblastic tumors. Am J Surg Pathol. 2016;40:1133–42.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–52.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Golfier F, Raudrant D, Frappart L, et al. First epidemiological data from the French Trophoblastic Disease Reference Center. Am J Obstet Gynecol. 2007;196:172.e1-172.e5.

    Article  PubMed  Google Scholar 

  46. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10.

    Article  CAS  PubMed  Google Scholar 

  47. Jorgensen JT. Twenty years with personalized medicine: past, present, and future of individualized pharmacotherapy. Oncologist. 2019;2019:432–40.

    Article  Google Scholar 

  48. Chen Y, Haiyan Ye H, Tang J, Weng Y, Zhang J, Liu J. Case report: first-line immune checkpoint inhibitor plus chemotherapy for oral metastasis in a patient with ultra high-risk gestational choriocarcinoma. Cancer Manag Res. 2022;14:1867–75.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Huang M, Pinto A, Castillo RP, Slomovitz BM. Complete serologic response to pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma. J Clin Oncol. 2017;35:3172–4.

    Article  CAS  PubMed  Google Scholar 

  50. Clair KH, Gallegos N, Bristow RE. Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: a case for immune checkpoint salvage therapy in trophoblastic tumors. Gynecol Oncol Rep. 2020;34: 100625.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Kazemi NY, Langstraat C, Weroha CS. Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: a case report and review of the literature. Gynecol Oncol Rep. 2022;39: 100923.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Porter A, Barcelon JM, Budker RL, et al. Treatment of metastatic placental site trophoblastic tumor with surgery, chemotherapy, immunotherapy and coil embolization of multiple pulmonary arteriovenous fistulate. Gynecol Oncol Rep. 2021;36: 100782.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. You B, Bolze PA, Jean-Pierre Lotz JP, et al. Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: cohort A of the TROPHIMMUN phase II trial. J Clin Oncol. 2020;38:3129–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Cheng H, Zong L, Kong Y, et al. Camrelizumab plus apatinib in patients with high- risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP-01): a single arm, open-label phase 2 study. Lancet Oncol. 2021;22:1609–17.

    Article  CAS  PubMed  Google Scholar 

  55. Abu-Rustum NR, Yashar CM,Bradley K et al (2022).Gestational Trophoblastic Neoplasia, Version 1. NCCN Clinical Practice Guidelines in Oncology. Online to NCCN.org

  56. Paulino E, de Melo AC. Immunotherapy in gestational trophoblastic neoplasia: great times are coming. Int J Gynecol Cancer. 2020;30:1654–5.

    Article  PubMed  Google Scholar 

  57. Worley MJ, Elias KM, Horowitz NS, Quade BJ, Berkowitz RS. Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: a case from the New England Trophoblastic Disease Center, Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Gynecol Oncol. 2018;148:5–11.

    Article  PubMed  Google Scholar 

  58. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Choi MC, Oh J, Lee C. Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia. Eur J Cancer. 2019;121:94–7.

    Article  PubMed  Google Scholar 

  60. Goldfarb JA, Dinoi G, Mariani A, Langstraat CL. A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab. Gynecol Oncol Rep. 2020;32: 100574.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Pisani D, Calleja-Agius J, Di Fiore R, et al. Epithelioid trophoblastic tumour: a case with genetic linkage to a child born over seventeen years prior, successfully treated with surgery and pembrolizumab. Curr Oncol. 2021;28:5346–55.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Bell SG, Uppal S, Sakala MD, Sciallis AP, Rolston A. An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab. Gynecol Oncol Rep. 2021;37: 100819.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Moffett A, Chazara O, Colucci F. Maternal allo-recognition of the fetus. Fertil Steril. 2017;107:1269–72.

    Article  PubMed  Google Scholar 

  64. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27:5932–43.

    Article  CAS  PubMed  Google Scholar 

  65. Wong AJ, Finch L, Pearson JM, Pinto A, Huang M. Retreatment of chemotherapy- resistant metastatic choriocarcinoma with immunotherapy. Gynecologic Oncology Reports. 2022;40: 100955.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Urosevic M, Dummer R. Human leukocyte antigen-G and cancer immunoediting. Cancer Res. 2008;68:627–30.

    Article  CAS  PubMed  Google Scholar 

  67. Joneborg U, Coopmans L, van Trommel N, Seckl M, Lok CAR. Fertility and pregnancy outcome in gestational trophoblastic disease. Int J Gynecol Cancer. 2021;31:399–411.

    Article  PubMed  Google Scholar 

  68. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. ZengW QS, Wang R, et al. PD-L1 blockage increases fetal resorption and Tfr cells but does not affect Tfh/Tfr ratio and B-cell maturation during allogeneic pregnancy. Cell Death Dis. 2020;11:119.

    Article  Google Scholar 

  70. Polnaszek B, Mullen M, Bligard K, Raghuraman N, Massad LS. Term pregnancy after complete response of placental site trophoblastic tumor to immunotherapy. Obstet Gynecol. 2021;138:115–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

I thank to Derya Gumurdulu (MD Prof) and Emine Kilic Bagir (MD Assoc Prof) for photgraphs 1 and 2 from the archieve of Cukurova University Faculty of Medicine Department of Pathology Division of Gynecologic Pathology

Funding

There is no funding source.

Author information

Authors and Affiliations

  1. Dept of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey

    Semra Paydas

Authors
  1. Semra Paydas
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication were done by SP. There is no role of the study sponsor(s).

Corresponding author

Correspondence to Semra Paydas.

Ethics declarations

Competing interests

There is no conflict of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paydas, S. Immune checkpoint inhibitor using in cases with gestational trophoblastic diseases. Med Oncol 40, 106 (2023). https://doi.org/10.1007/s12032-022-01941-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-022-01941-3

Keywords

Search

Navigation